IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Invivyd, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.61−0.01 (-1.39%)

Close on Oct 19, 2026

Market cap: $195.47M
P/E (TTM): –
Dividend yield: –

Dividends

Invivyd has not reported a dividend

No dividend per share appears in Invivyd's annual filings since fiscal 2020.

Where these numbers come from

Parsed from the XBRL in Invivyd's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IVVD.

Revenue growth26.3% · median 134.8%

Operating margin-192.8% · median -311.6%

Net margin-183.9% · median -259.4%

Company	Revenue	Growth
VIR	$303.23M	+1495.9%
KYMR	$105.00M	+134.8%
PLX	$80.62M	+30.1%
VRDN	$71.13M	+23220.3%
IVVD	$58.37M	+26.3%
CHRS	$50.94M	+61.0%

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 122
Held by institutions: 79.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1832038

Advertisement
300 × 250